Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors (Q43244727)

From Wikidata

Jump to navigation Jump to search

scientific article published in September 2009

Language	Label	Description	Also known as
English	Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors	scientific article published in September 2009

Statements

scholarly article

1 reference

Europe PubMed Central

17 November 2017

Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors (English)

1 reference

Europe PubMed Central

17 November 2017

author name string

Atsuo Tahara

1

1 reference

Europe PubMed Central

17 November 2017

Akiko Matsuyama-Yokono

2

1 reference

Europe PubMed Central

17 November 2017

Ryosuke Nakano

3

1 reference

Europe PubMed Central

17 November 2017

Yuka Someya

4

1 reference

Europe PubMed Central

17 November 2017

Masahiko Hayakawa

5

1 reference

Europe PubMed Central

17 November 2017

Masayuki Shibasaki

6

1 reference

Europe PubMed Central

17 November 2017

publication date

1 September 2009

1 reference

Europe PubMed Central

17 November 2017

Pharmacological Reports

1 reference

Europe PubMed Central

17 November 2017

61

1 reference

Europe PubMed Central

17 November 2017

899-908

1 reference

Europe PubMed Central

17 November 2017

5

1 reference

Europe PubMed Central

17 November 2017

Glibenclamide-associated hypoglycaemia: a report on 57 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interactions between insulin resistance and insulin secretion in the development of glucose intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes and obesity: the twin epidemics

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970147-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1734-1140(09)70147-1

1 reference

Europe PubMed Central

17 November 2017

1 reference

Europe PubMed Central

17 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43244727&oldid=1984731828"